Clinical and Molecular Characteristics May Alter Treatment Strategies of Thyroid Malignancies in DICER1 Syndrome

Karin Van Der Tuin, Leanne De Kock, Eveline J. Kamping, Sabine E. Hannema, Marie Jose M. Pouwels, Marek Niedziela, Tom Van Wezel, Frederik J. Hes, Marjolijn C. Jongmans, William D. Foulkes, Hans Morreau*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Context DICER1 syndrome is a rare autosomal-dominantly inherited disorder that predisposes to a variety of cancerous and noncancerous tumors of mostly pediatric and adolescent onset, including differentiated thyroid carcinoma (DTC). DTC has been hypothesized to arise secondarily to the increased prevalence of thyroid hyperplastic nodules in syndromic patients. Objective To determine somatic alterations in DICER1-associated DTC and to study patient outcomes. Design Retrospective series. Setting Tertiary referral centers. Patients Ten patients with germline pathogenic DICER1 variants and early-onset DTC. Methods Somatic DICER1 mutation analysis, extensive somatic DNA variant and gene fusion analyses were performed on all tumors. Results Median age at DTC diagnosis was 13.5 years and there was no recurrent or metastatic disease (median follow-up, 8 years). All thyroid specimens showed diffuse nodular hyperplasia with at least one focus suspicious of DTC but without infiltrative growth, extrathyroidal extension, vascular invasion, or lymph node metastasis. Most of the individual nodules (benign and malignant) sampled from the 10 tumors harbored distinct DICER1 RNase IIIb hotspot mutations, indicating a polyclonal composition of each tumor. Furthermore, nine of 10 DICER1-related DTCs lacked well-known oncogenic driver DNA variants and gene rearrangements. Conclusion On the basis of our clinical, histological, and molecular data, we consider that most DICER1-related DTCs form a low-risk subgroup. These tumors may arise within one of multiple benign monoclonal nodules; thus, hemi-thyroidectomy or, more likely, total thyroidectomy may often be required. However, radioiodine treatment may be unnecessary given the patients' ages and the tumors' low propensity for metastases.

Original languageEnglish
Pages (from-to)277-284
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume104
Issue number2
DOIs
Publication statusPublished - 9 Nov 2018

Cite this